Impact of Pretreatment Systemic Inflammatory Markers on Treatment Persistence with Biologics and Conventional Systemic Therapy: A Retrospective Study of Patients with Psoriasis Vulgaris and Psoriatic Arthritis

Systemic inflammation plays a central role in the pathophysiology of psoriasis. This study examined accessible systemic inflammatory markers in patients with psoriasis vulgaris and psoriatic arthritis. We aimed to evaluate their association with psoriasis severity, the presence of arthritis, and drug continuation rates. The findings revealed that neutrophil, monocyte, and platelet count, neutrophil/lymphocyte ratio, monocyte/lymphocyte ratio, systemic inflammation response index, systemic immune/inflammation index (SII), and CRP were positively correlated with Psoriasis Area and Severity Index scores. Patients presenting with higher platelet/lymphocyte ratio (PLR) or CRP values were more likely to be diagnosed with psoriatic arthritis than with psoriasis vulgaris in the multivariate regression analysis. Importantly, patients with higher pretreatment neutrophil or platelet count, PLR, and SII were associated with lower treatment continuation rates of conventional systemic agents. Higher pretreatment scores of systemic inflammatory markers did not affect treatment retention rates of biologics. These findings suggest that several accessible systemic inflammatory markers may effectively assess underlying systemic inflammation and may provide an indication for a therapeutic approach in patients with psoriasis vulgaris and psoriatic arthritis.

[1]  Chunping Liu,et al.  Immunity: Psoriasis comorbid with atherosclerosis , 2022, Frontiers in Immunology.

[2]  T. Gambichler,et al.  The Role of Hormones in Hidradenitis Suppurativa: A Systematic Review , 2022, International journal of molecular sciences.

[3]  Q. Dong,et al.  IL-17A and TNF-α inhibitors induce multiple molecular changes in psoriasis , 2022, Frontiers in Immunology.

[4]  F. Morel,et al.  Ex vivo cytokine production in psoriatic disease: Towards specific signatures in cutaneous psoriasis and peripheral psoriatic arthritis , 2022, Frontiers in Immunology.

[5]  P. Jankowski,et al.  Investigation of the Associations of Novel Inflammatory Biomarkers—Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI)—With the Severity of Coronary Artery Disease and Acute Coronary Syndrome Occurrence , 2022, International journal of molecular sciences.

[6]  D. Zillikens,et al.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases , 2022, Frontiers in Medicine.

[7]  T. Gambichler,et al.  Complete blood collection‐based systemic inflammation biomarkers for patients with hidradenitis suppurativa , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  Hong-Zhong Jin,et al.  Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients , 2021, BMC Immunology.

[9]  A. Pawlik,et al.  Role of Janus Kinase Inhibitors in Therapy of Psoriasis , 2021, Journal of clinical medicine.

[10]  Y. Asano,et al.  Prognostic Relevance of Pretreatment Peripheral Neutrophil Count and Neutrophil-to-lymphocyte Ratio in Primary Cutaneous Angiosarcoma , 2021, Acta dermato-venereologica.

[11]  T. Honda,et al.  Pathophysiology of psoriasis: A review , 2021, The Journal of dermatology.

[12]  Shuohua Chen,et al.  The Associations of Two Novel Inflammation Indexes, SII and SIRI with the Risks for Cardiovascular Diseases and All-Cause Mortality: A Ten-Year Follow-Up Study in 85,154 Individuals , 2021, Journal of inflammation research.

[13]  A. Yorulmaz,et al.  Systemic Immune-Inflammation Index (SII) Predicts Increased Severity in Psoriasis and Psoriatic Arthritis , 2020, Current health sciences journal.

[14]  S. Pennington,et al.  Applying precision medicine to unmet clinical needs in psoriatic disease , 2020, Nature Reviews Rheumatology.

[15]  A. Armstrong,et al.  Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. , 2020, JAMA.

[16]  Yenn-Jiang Lin,et al.  Systemic immune‐inflammation index (SII) predicted clinical outcome in patients with coronary artery disease , 2020, European journal of clinical investigation.

[17]  E. Fisher,et al.  Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1 , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[18]  Y. Tada,et al.  Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review , 2020, International journal of molecular sciences.

[19]  K. Schäkel,et al.  Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis , 2020, Nature Communications.

[20]  Asmaa M. El-Nasser,et al.  Role of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, Mean Platelet Volume in Egyptian Patients with Psoriasis Vulgaris. , 2020, The Egyptian journal of immunology.

[21]  K. Schäkel,et al.  Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis , 2019, Nature Communications.

[22]  W. Boehncke,et al.  IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications , 2020, Frontiers in Immunology.

[23]  K. Moore,et al.  Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis , 2019, Science Translational Medicine.

[24]  N. Korman Management of psoriasis as a systemic disease: what is the evidence? , 2019, The British journal of dermatology.

[25]  T. Hwang,et al.  Neutrophils in Psoriasis , 2019, Front. Immunol..

[26]  Robert A. Campbell,et al.  TNF-alpha driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. , 2019, Blood.

[27]  A. Mangoni,et al.  Meta‐analysis of neutrophil‐to‐lymphocyte and platelet‐to‐lymphocyte ratio in rheumatoid arthritis , 2018, European journal of clinical investigation.

[28]  A. Mangoni,et al.  Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis , 2018, Clinical and Experimental Medicine.

[29]  M. Clerici,et al.  Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: A meta-analysis , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[30]  T. Gambichler,et al.  Interleukin‐36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop , 2018, The British journal of dermatology.

[31]  J. O’Shea,et al.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases , 2017, Nature Reviews Drug Discovery.

[32]  G. Bugdayci,et al.  Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in Turkish patients with chronic plaque psoriasis. , 2017, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

[33]  H. Nakagawa,et al.  Neutrophil–lymphocyte ratio, platelet–lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics , 2017, The Journal of dermatology.

[34]  B. Goker,et al.  The Association Between Neutrophil/Lymphocyte Ratio and Disease Activity in Rheumatoid Arthritis and Ankylosing Spondylitis , 2016, Journal of clinical laboratory analysis.

[35]  M. Afari,et al.  Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update , 2016, Expert review of cardiovascular therapy.

[36]  Do Young Kim,et al.  Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis , 2016, The Journal of dermatology.

[37]  S. Ann,et al.  Combined Usefulness of the Platelet-to-Lymphocyte Ratio and the Neutrophil-to-Lymphocyte Ratio in Predicting the Long-Term Adverse Events in Patients Who Have Undergone Percutaneous Coronary Intervention with a Drug-Eluting Stent , 2015, PloS one.

[38]  T. Kadowaki,et al.  Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells , 2015, Nature Communications.

[39]  A. Armstrong,et al.  Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. , 2015, JAMA dermatology.

[40]  S. Clarke,et al.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.

[41]  Ahmad H Alghadir,et al.  Role of cellular oxidative stress and cytochrome c in the pathogenesis of psoriasis , 2012, Archives of Dermatological Research.

[42]  W. Boehncke,et al.  The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity , 2011, Experimental dermatology.

[43]  M. Karakawa,et al.  Adiponectin as an anti‐inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy , 2011, The British journal of dermatology.

[44]  L. Naldi,et al.  Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. , 2010, Clinics in dermatology.

[45]  D. Mcgonagle,et al.  Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[46]  M. Komine,et al.  Serum high molecular weight adiponectin levels are decreased in psoriasis patients. , 2009, Journal of dermatological science.

[47]  W. Gulliver Long‐term prognosis in patients with psoriasis , 2008, The British journal of dermatology.

[48]  B. Rogala,et al.  Platelet function in cutaneous diseases , 2008, Platelets.

[49]  M. Gawaz,et al.  Platelets in inflammation and atherogenesis. , 2005, The Journal of clinical investigation.

[50]  Mark Lebwohl,et al.  Psoriasis , 1906, The Lancet.

[51]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.